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This review will focus on the current state of knowledge regarding non-coding RNAs
(ncRNA) in stroke and neuroprotection. There will be a brief introduction to microRNAs
(miRNA), long ncRNAs (lncRNA), and piwi-interacting RNAs (piRNA), followed by evidence
for the regulation of ncRNAs in ischemia. This review will also discuss the effect of neuro-
protection induced by a sublethal duration of ischemia or other stimuli given before a stroke
(preconditioning) on miRNA expression and the role of miRNAs in preconditioning-induced
neuroprotection. Experimental manipulation of miRNAs and/or their targets to induce pre-
or post-stroke protectionwill also be presented, as well as discussion onmiRNA responses
to current post-stroke therapies.This review will conclude with a brief discussion of future
directions for ncRNAs studies in stroke, such as new approaches to model complex ncRNA
datasets, challenges in ncRNA studies, and the impact of extracellular RNAs on human
diseases such as stroke.
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INTRODUCTION
Despite advances in preclinical studies that have established mech-
anisms of cell death in brain ischemia and identified potential
strategies to prevent or treat brain injury following stroke, few
of these advances have successfully translated into clinical prac-
tice. Endogenous neuroprotective responses have been studied in
experimental stroke largely using a model wherein a sublethal
duration of ischemia is given before a stroke (preconditioning).
However, additional methods of preconditioning are also effec-
tive in reducing stroke injury, i.e., hypoxia, anesthetic agents, and
activation of Toll-like receptors, and natural states of neuropro-
tection in animals such as hibernation that lend important insight
to the topic. More recent efforts have focused on strategies for
neuroprotection after a stroke (post-conditioning), which is more
relevant to the clinical presentation in human patients. This review
will present the current state of knowledge regarding evidence
for specific families of non-coding RNAs (ncRNA) in experi-
mental stroke and neuroprotection: microRNAs (miRNA), long
non-coding RNAs (lncRNA),and piwi-interacting RNAs (piRNA).
The literature search was performed using PUBMED queried with
a combination of terms listed in Table 1, and the number of
references returned for each query.
In recent years, there has been increasing focus on the role
of ncRNAs as regulators of post-transcriptional gene expression,
and of responses to ischemia and neuroprotection (1). Spinal
cord injury and traumatic brain injury also lead to changes
in miRNA expression that precedes injury (2). Further, dys-
regulation of ncRNA activities has been closely linked to the
pathophysiology of cerebral vascular endothelium and neuro-
logic functional disorders in the brain’s response to ischemia
(3). Experimental stroke models have been used for global pro-
filing of brain or blood miRNAs in animals, or to manipulate
specific miRNAs or their targets to examine their potential as
neuroprotective strategies for stroke. Given the current pub-
lished reviews for the role of miRNAs in the occurrence and
development of post-stroke depression (4), and in the regula-
tion of miRNAs that lead to angiogenesis and remyelination (5),
neurogenesis (6), and spontaneous recovery (7), they will not be
discussed here. Also, outside the scope of this review are many
miRNAs studies on cardiac ischemia and protection that may
provide important insights on miRNAs in cerebral ischemia and
neuroprotection (8).
NON-CODING RNAs
Early biochemistry studies identified three families of RNA that
function cooperatively in the process of protein synthesis: mes-
senger, transfer, and ribosomal RNA. Messenger RNAs (mRNA)
carry genetic information copied from DNA in a series of three-
base codes that specify a particular amino acid, specifying the
polypeptide sequence. Transfer RNAs (tRNA) carry and bind a
complementary amino acid to the growing end of a polypep-
tide chain. Ribosomal RNAs (rRNA) bind to protein complexes,
which physically move along mRNAs and catalyze the assembly
of amino acids into polypeptide chains (9). Additional families
of ncRNAs that play essential roles in the processes of protein
synthesis were subsequently discovered (10). For example, small
nuclear RNAs (snRNA) bind to proteins to form spliceosomes that
process pre-mRNA into mature mRNA in the nucleus (11), while
small nucleolar RNAs (snoRNA) guide chemical modifications of
other RNAs (12). This review will focus on three newer families
of ncRNAs; (1) miRNAs that regulate post-transcriptional gene
expression, largely by direct effects on mRNAs (13), (2) lncRNAs
that can regulate transcription and translation, and act as epi-
genetic modifiers, and (3) piRNAs that largely exert effects on
transcription and genomic maintenance. The reader is directed to
a 2014 Frontiers in Cellular Neuroscience Research Topic entitled
“Regulatory RNAs in the Nervous System” for comprehensive dis-
cussions regarding the biosynthesis and function of these ncRNAs,
as well as a recent review entitled “Non-Coding RNAs as Potential
Neuroprotectants against Ischemic Brain Injury,” which beautifully
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Table 1 | Literature search strategy.
Search terms Number of
references
Ischemic
preconditioning
Cerebral Review 104
Neuroprotection Cerebral ischemia MiRNA 10
Preconditioning Cerebral ischemia MiRNA 5
Stroke MiRNA 4
Post-conditioning Cerebral ischemia MiRNA 0
Stroke MiRNA 1
MiRNA Stroke 78
Ischemia 147
Preconditioning 23
Neuroprotection 28
Neuroprotection Ischemia 12
Neuroprotection Cerebral ischemia 46
Neuroprotection Cerebral ischemia 10
Ischemic stroke 9
Biomarker Cerebral ischemia 2
Biomarker Stroke 9
PiRNA Brain 9
Stroke 1
Ischemia 1
Preconditioning 0
Neuroprotection 0
Neuroprotection Ischemia 0
Cerebral ischemia 1
Neuroprotection Cerebral ischemia 0
Neuroprotection Ischemic stroke 0
LncRNA Brain 56
Stroke 2
Ischemia 3
Preconditioning 0
Neuroprotection 0
Neuroprotection Ischemia 0
Cerebral ischemia 2
Exosome MiRNA Cerebral ischemia 0
Cerebral ischemia 0
Stroke 4
Post-stroke MiRNA 1
PUBMED was queried with the following combination of search terms, and the
resultant numbers of references returned for each combination are listed.
depicts the current understanding of the biogenesis pathways for
each of these three ncRNAs discussed herein (14).
MicroRNAs
The miRNAs are the most well-characterized family of ncRNA to
date. Mature, functional miRNA sequences are ~21–23 nucleotides
(nt) in length, and are most recognized for their roles in the reg-
ulation of post-transcriptional gene expression via direct effects
on the 3′-untranslated region (3′UTR) of mRNAs that lead to
translational repression or mRNA degradation. MiRNA biogen-
esis has been previously described and will not be presented
here, but the reader is guided to a recent comprehensive review
of this topic (15). The miRNAs are particularly abundant in
the nervous system where they serve as effectors of brain
development (16–18) and maintenance of the neuronal pheno-
type (19, 20). MiRNAs also drive the maturation of dendrites
and spines (21–23) and serve as effectors of synaptic plas-
ticity and function (24–30). Emerging studies highlight roles
for miRNAs in extracellular vesicles (EVs) where they con-
tribute to cell–cell communication in the brain (31–33) and
throughout the nervous system (34). As such, dysregulation of
EVs may underlie diverse neurological disorders including brain
tumors (35), neurodegeneration, and neuroinflammation (34),
and EVs in biofluids are currently being evaluated for their
potential as biomarkers or therapeutic strategies for the treat-
ment or prevention of human diseases, including many brain
disorders (36).
Long non-coding RNAs
The lncRNAs are >200 nt in size, and they differ greatly from
each other with respect to their size, interacting partners, and
modes of action (37). The lncRNAs are processed through path-
ways similar to those of protein-coding genes, and have similar
histone-modification profiles, splicing signals, and exon/intron
lengths. The complex intergenic, overlapping, and antisense pat-
terns of lncRNAs relative to adjacent protein-coding genes suggests
that many lncRNAs regulate the expression of adjacent protein-
coding genes. LncRNAs are also implicated in the regulation of
transcription and post-transcriptional gene expression, as com-
prehensively reviewed (38). LncRNAs can stabilize or promote
the translation of target mRNAs through extended base pairing,
or they can inhibit target mRNA translation or facilitate mRNA
decay via partial base pairing. Even in the absence of any base
pair complementarity, lncRNAs can suppress precursor mRNA
splicing and translation by acting as decoys for RNA-binding pro-
teins or miRNAs, or compete for miRNA-mediated inhibition of
mRNAs resulting in increased expression of corresponding pro-
teins. Over one-half of all lncRNAs are expressed in the brain (39)
and they regulate many CNS processes (40). Hence, dysregulation
of lncRNAs can also contribute to CNS pathologies such as neu-
rodegeneration, neuroimmunological disorders, primary brain
tumors, and psychiatric diseases (41). As such, lncRNAs present
new targets for the understanding, diagnosis, and treatment of
CNS disorders (42).
Piwi-interacting RNAs
The piRNAs are ~25–33 nt in length, depending on the PIWI
protein group they bind to, and they lack sequence conservation
between organisms. Recent reviews highlight the complexity of
piRNA biogenesis pathways, which have just begun to be elu-
cidated (43, 44). PiRNA biogenesis pathways are complicated
as they are distinct in individual organisms, and they are dis-
tinct from miRNA pathways in that there is no evidence for a
double-stranded RNA precursor and biogenesis is independent
of Dicer (45–47). There are two proposed pathways for gener-
ating piRNAs: a primary processing pathway and a “ping-pong”
amplification loop, as recently reviewed (14). PiRNA clusters are
transcribed in the sense or antisense direction, and the long
single-stranded RNA serves as the basis for piRNA production.
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The piRNAs protect germline cells from transposons in organ-
isms as they guide PIWI proteins to complementary RNAs derived
from transposable elements, and then the PIWI proteins cleave
transposon RNA. Transposons are genetic elements that copy
themselves to RNA, then back to DNA, and then integrate back
into the genome where they may induce mutations that cause
disease by inserting near or within other genes to disrupt their
function. The piRNAs have been dubbed as the guardians of the
genome because of their ability to silence deleterious retrotrans-
posons (48). Very recent studies also show piRNAs as effectors
in the epigenetic control of long-term memory storage in the
brain (49).
Together, these three newer families of ncRNAs serve to regulate
many aspects of cellular biology that ultimately control pheno-
type, function, and genomic integrity. As such, dysregulation of
any or all of these ncRNAs will likely have profound impact on
CNS disorders.
ISCHEMIA
OVERALL EFFECT OF ISCHEMIA ON miRNA EXPRESSION
The overall effect of stroke on miRNA expression in brain and
blood has been examined in experimental rodent models and in
human subjects. Most rodent studies have used transient mid-
dle cerebral artery occlusion (MCAO) to induce focal cerebral
ischemia. The first such study used microarray analysis to exam-
ine overall expression of miRNAs in rat brain and blood at 24
and 48 h after ischemia and showed that miRNAs are regulated
by focal ischemia and may potentially serve as blood biomarkers
for ischemia (50). Focal ischemia studies in spontaneously hyper-
tensive rats also showed altered miRNA profiles at all reperfusion
times examined (3 h to 3 days), with several miRNAs altered at
multiple time points (51). Bioinformatic analysis predicted mRNA
targets of the ischemia-regulated miRNAs as proteins known to
mediate inflammation, transcription, neuroprotection, receptor
function, and ionic homeostasis (51). Further, in silico analysis
of 8 ischemia-induced miRNAs revealed sequence complemen-
tarity to 877 gene promoters, suggesting that ischemia-regulated
miRNAs directly modulate gene expression. Importantly, these
studies also showed that focal ischemia did not alter mRNA lev-
els for Drosha, Dicer, Pasha, and Exportin-5, proteins involved in
the miRNA biogenesis pathway (51). Studies focused on humans
revealed that circulating blood miRNA profiles were altered in
young ischemic stroke patients (18–49 years) and that specific
miRNAs that could classify subtypes of stroke (large-vessel ath-
erosclerosis vs. small-vessel disease vs. cardioembolism) were still
detectable in blood several months after injury (52). The first
RNAseq studies identified significant changes in 78 known and
24 novel miRNAs in rat brain following ischemia, and Kyoto
Encyclopedia of Genes and Genomes (KEGG) pathway analysis
predicted that protein targets of these miRNAs function in sig-
naling transduction, MAPK signaling, NF-kappaB signaling, and
neurotrophin signaling (53).
Together, these studies show that miRNAs are regulated in brain
and blood where they likely regulate translation, and transcription,
in post-ischemic brain. These studies also established the potential
for blood miRNAs to be developed as clinical biomarkers for the
diagnosis and prognosis of ischemic stroke in humans.
SEX-SPECIFIC miRNA RESPONSES TO ISCHEMIC INJURY
Females are more resistant to stroke injury than males until
menopause (54), and responses to experimental stroke and cell
death are sexually dimorphic (55). In males, stroke initiates mito-
chondrial release of apoptosis-inducing factors that result in
caspase-independent cell death, while in females stroke primar-
ily triggers mitochondrial cytochrome c release and subsequent
caspase activation. At baseline, females have higher levels than
males of brain mRNA for X-linked inhibitor of apoptosis (XIAP),
the primary endogenous inhibitor of caspases, and stroke sig-
nificantly decreases XIAP mRNA in females but not in males.
However, XIAP protein levels are decreased in both sexes after
stroke, likely due to different levels of miR-23a, which binds to the
XIAP 3′UTR, in male and female ischemic brain (55). Subsequent
studies also revealed distinct differences in miRNA responses to
ischemia in male and female brain, as well as a signature miRNA
response to ischemia common to males and females (56). The
finding that there are sex differences in miRNA expression dur-
ing development in rat cortex may bear on differential responses
to ischemia in adults (57). Accordingly, a recent study investi-
gated the impact of age and sex on miRNA expression in adult
(6 months) and middle-aged (11–12 months) female and male
rats subjected to the endothelin-1 model of MCAO (58). Consis-
tent with MCAO injury, infarct volume and sensory-motor deficits
were significantly reduced in adult females compared with middle-
aged females, adult males, or middle-aged males. Analysis of blood
at 2 days post-stroke revealed 21 differentially regulated circu-
lating miRNAs, and principal component analysis demonstrated
that most of the variance was due to age. At 5 days post-stroke,
analysis of blood revealed 78 differentially regulated circulating
miRNAs, and principal component analysis confirmed that most
of the variance was associated with sex. Brain miRNAs analyzed at
5 days post-stroke revealed a small cohort of miRNAs (miR-15a,
miR-19b, miR-32, miR-136, and miR-199a-3p) highly expressed
exclusively in adult females. These patterns of circulating miRNA
expression suggest that age is the primary influence on the initial
severity of stroke pathology, but sex is the primary influence on
recovery from stroke. Together, these studies support that miRNA
expression can be different between males and females, which may
contribute to sexually dimorphic responses to ischemia.
EFFECT OF ISCHEMIA ON SPECIFIC miRNAs AND TARGETS
Subsequent studies began to investigate the functional significance
of individual ischemia-regulated miRNAs on the molecular mech-
anisms that lead to brain cell death. In addition to those described
above, several of these specific miRNAs are discussed below.
miR-497
The expression of miR-497 was significantly induced in mouse
brain 24 h after MCAO, and in mouse N2A neuroblastoma (N2A)
cells after in vitro ischemia induced by oxygen-glucose depriva-
tion (OGD) (59). Yin and colleagues showed a direct correlation
between miR-497 and cell death: gain or loss of miR-497 pro-
moted or decreased OGD-induced neuronal cell loss, respectively.
Luciferase assays showed direct binding of miR-497 to the 3′UTR
of B-cell lymphoma 2 (Bcl-2) and Bcl-w mRNAs, whose pro-
teins function as key regulators in attenuating stroke-induced
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apoptotic cell death (60–63). Inhibition of miR-497 in mouse
brain enhanced Bcl-2/-w protein expression in the ischemic region,
attenuated ischemic brain infarction, and improved neurological
outcomes in response to focal ischemia.
miR-29b
Subsequent studies showed that miR-29b promoted ischemic cell
death by targeting Bcl-2. MiR-29b expression was significantly
increased in rat brain by focal ischemia, and in primary cultured
neurons by OGD (64). Cell death was also directly correlated
with miR-29b expression: gain or loss of miR-29b promoted or
decreased OGD-induced neuronal cell loss, respectively. Addi-
tionally, miR-29b directly bound to the 3′UTR of Bcl-2 mRNA,
and overexpression of the bcl-2 gene rescued neuronal cell death
induced by miR-29b.
miR-134
Overexpression of miR-134 promoted hippocampal cell death in
cultured neurons subjected to OGD, while inhibition of miR-
134 was protective. Expression of cyclic AMP (cAMP) response
element-binding protein (CREB), a putative target of miR-134,
was inversely regulated by miR-134 (65).
miR-21
In situ hybridization showed increased expression of miR-21 in
rat neurons in the ischemic boundary zone at 2 and 7 days after
embolic MCAO, and RT-qPCR studies verified a quantitative
increase in mature miR-21 in neurons isolated from the ischemic
boundary zone (66). Overexpression of miR-21 protected cortical
neurons from cell death induced by OGD, while inhibition of miR-
21 promoted OGD-induced cell death. Overexpression of miR-21
in neurons significantly reduced levels of Fas Ligand (FASLG),
a cell death-inducing ligand, and luciferase assays showed that
miR-21 binds to the 3′UTR of FASLG mRNA.
miR-347
Permanent focal cerebral ischemia in rat brain also leads to reg-
ulation of miRNAs between 3 h and 14 days following MCAO
(67). Of particular interest was miR-347 that was upregulated
at both acute and late phases following ischemia. Overexpres-
sion of miR-347 increased neuronal apoptosis and induced the
expression of novel mRNA targets including acyl-CoA synthetase
long-chain family member 4 (Acsl4), Bcl-2/adenovirus E1B 19 kDa
protein-interacting protein 3-like (Bnip3l), and phytanoyl-CoA
2-hydroxylase interacting protein (Phyhip) (67).
These independent studies demonstrate that although there
are diverse miRNAs regulated by ischemia, multiple miRNAs act
directly and indirectly on cell-death proteins and can influence
both pro- and anti-apoptotic pathways.
TEMPORAL AND REGIONAL EXPRESSION OF SPECIFIC miRNAs IN
ISCHEMIA
MiRNAs can induce distinct outcomes in a temporal- and cell-
specific manner. Cultured rat cortical neurons and astrocytes
subjected to OGD exhibit unique miRNA expression patterns.
OGD increased miR-29b expression in neurons by twofold after
6 h and by fourfold after 24 h compared to miR-21 that remained
unchanged until after 24 h of OGD (68). However, OGD increased
miR-29b and miR-21 in astrocytes only after 12 h, and further,
altered expression of miR-30b, miR-107, and miR-137 was specific
to astrocytes. Responses to ischemia in mouse brain also showed
increased expression of miR-181 in the core, where cells die, and
decreased expression of miR-181 in the penumbra, where cells sur-
vive (69). Reduction in miR-181a was correlated with increased
levels of glucose-regulated protein, 78 kDa (GRP78), a heat shock
protein that functions within the chaperone network to increase
resistance to and improve recovery from ischemic brain injury
(69, 70). Further studies compared miRNA expression induced
by OGD in rat cortical neurons to in vivo miRNA expression in
mice exposed to the three-vessel occlusion model of ischemia (71).
These studies showed that while multiple miRNAs were differen-
tially regulated by ischemia in each model, miR-19b, miR-29b-2*,
and miR-339-5p were all significantly upregulated in common to
both models (71). These studies suggest that there are signature
miRNA responses to ischemia in salvageable brain regions, infor-
mation that may lend new insights into cell- and temporal-specific
protective strategies for the treatment of ischemia.
lncRNAs IN ISCHEMIA
The effect of ischemia on lncRNA expression was first examined in
adult male spontaneously hypertensive rats at 3, 6, and 12 h after
MCAO (72). The results showed that of 8314 lncRNAs analyzed,
443 were significantly changed at all time points (359 upregulated
and 84 downregulated). Of these, 61 stroke-responsive lncRNAs
showed >90% sequence homology with exons of protein-coding
genes, but in vitro translation of these lncRNAs did not form any
protein products (72). Based on the roles of lncRNAs in cellular
homeostasis during development and disease via interactions with
chromatin-modifying proteins (CMPs), the effect of ischemia on
the association of lncRNAs with CMPs, Sin3A, and corepressors
of the RE1 (Repressor Element 1)-silencing transcription factor
(coREST) was examined (73). These studies revealed that 177 of
the 2497 lncRNAs in rat cerebral cortex showed increased binding
to either Sin3A or coREST following ischemia, and that of these,
26 lncRNAs enriched with Sin3A and 11 lncRNAs enriched with
coREST were upregulated by ischemia. Thus, these studies sug-
gest that ischemia-induced lncRNAs might associate with CMPs
to modulate the post-ischemic epigenetic landscape.
piRNAs IN ISCHEMIA
The first evidence for expression of piRNAs in the nervous sys-
tem was revealed by RNAseq analysis of mouse hippocampal RNA
(74). PiRNA expression in adult male spontaneously hypertensive
rats examined 24 h after focal ischemia revealed that of ~40,000
piRNAs analyzed, 105 piRNAs were significantly altered in cerebral
cortex with 54 upregulated and 51 downregulated (75). Bioinfor-
matic analysis of four of the top stroke-responsive piRNAs (two
up, two down) revealed that their transposon targets belong exclu-
sively to the class of retrotransposons. Further, analysis of the
promoter region of 10 stroke-responsive piRNAs revealed binding
sites for 159 transcription factors, including the zinc finger, Krup-
pel, and E2F transcription factor-like families, supporting that
transcription factors control the expression of stroke-responsive
piRNAs.
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NEUROPROTECTION
PRECONDITIONING
The studies discussed here will focus only on miRNA responses
to preconditioning models that lead to neuroprotection against
stroke as there are no published studies regarding the impact
of post-conditioning on miRNA, lncRNA, or piRNA in cerebral
ischemia to date. Preconditioning is a phenomenon whereby a
brief, non-lethal duration of a stimulus induces a transient state of
resistance (tolerance) to a subsequent lethal duration of a stimu-
lus. Ischemic preconditioning (IPC) is an experimental technique
induced by a short duration of ischemia that protects the brain
from a subsequent injurious duration of ischemia (76, 77). New
protein synthesis is required for IPC-induced tolerance (78), and
the signature of ischemic tolerance is global repression of gene
expression (79–81). However, additional preconditioning stim-
uli such as hypoxia, anesthesia, and activation of the Toll-like
receptors can induce tolerance and protection against ischemia,
as discussed below.
Ischemic preconditioning
Ischemic tolerance was first examined in a gerbil model of
global cerebral ischemia (82, 83). The first studies to examine
miRNA responses to ischemia in mice evaluated their expression
in response to IPC (15 min MCAO), ischemia (60 min MCAO),
and tolerance (15 min MCAO, 72 h reperfusion, 60 min MCAO).
Microarray analysis of cortical tissue isolated from adult male mice
24 h after each treatment revealed that miRNAs were regulated by
each treatment with 192 upregulated and 95 downregulated by
IPC, and that there was very little overlap in the miRNAs reg-
ulated between all three treatment groups (84). Bioinformatic
analysis focused on those miRNAs downregulated by IPC that
could result in increased protein synthesis revealed that pre-
dicted targets included transcriptional regulators such as methyl
cytosine-phosphate-guanine (CpG) binding protein 2 (MeCP2)
(84). MecCP2 is a global transcriptional regulator that largely
serves to repress gene expression but can also activate gene expres-
sion (85). MeCP2 protein, but not mRNA expression, increased
in mouse cortex by 8 h after IPC, and MeCP2 knockout mice
showed increased sensitivity to the preconditioning stimulus and
were not tolerant to a subsequent ischemic event (84). Recent
studies in a cardiac ischemia model showed that mesenchymal
stem cells, which protect ischemic cardiomyocytes by secretion of
paracrine factors, secreted exosomes enriched with miR-22 follow-
ing IPC, and uptake of these exosomes by cardiomyocytes reduced
ischemia-induced apoptosis via direct targeting of MeCP2 (86).
These studies support a protective role for MeCP2 in both cere-
bral and cardiac ischemia, although the specific gene targets in
each model need to be identified.
Analogous studies to examine miRNA expression in a rat model
of IPC induced in adult male spontaneously hypertensive rats by
10 min MCAO revealed significant changes in 51 miRNAs (26
upregulated and 25 downregulated) at 6 h of reperfusion, and 20
of these miRNAs remained altered 3 days after IPC (87). Bioin-
formatic analysis of the miRNAs and KEGG Pathway analysis
of their predicted targets showed MAP-kinase and mammalian
target of rapamycin (mTOR) signaling as the top two pathways
targeted by the upregulated miRNAs, and Wnt and gonadotropin
releasing hormone (GnRH) signaling as the top two pathways tar-
geted by the downregulated miRNAs. Interestingly, these studies
also showed that multiple miRNAs downregulated by IPC were
predicted to target MeCP2 in rat, consistent with previous studies
on IPC in mouse (84).
Additional studies in adult male mice subjected to IPC or
ischemia revealed 8 miRNAs that together comprise the miR-200
and miR-182 families of miRNAs that were selectively upregu-
lated 3 h after IPC, and 2 miRNAs (miR-681 and miR-197) that
were selectively upregulated 24 h after IPC (88). No miRNAs were
downregulated at 3 h after IPC, and only 1 miRNA (miR-468) was
downregulated at 24 h after IPC. Transfection of the 8 IPC upregu-
lated miRNAs into N2A cells revealed 5 miRNAs that increased cell
survival in response to OGD, and decreased expression of prolyl
hydroxylase 2 (PHD2), a predicted target of the miR-200 fam-
ily involved in the ubiquitin/proteosomal pathway. Reduced levels
of PHD2 protein were also detected 24 h after IPC, but not after
ischemia.
Hypoxic preconditioning
Hypoxic preconditioning (HPC) induced by autohypoxia (acute
and repetitive exposure to progressive hypoxia) in adult male mice
significantly decreased ischemic injury by mechanisms involving
multiple conventional protein kinase C βII (cPKCβII)-interacting
proteins (89). Bioinformatic analysis of 17 miRNAs (4 upregu-
lated and 13 downregulated) in mouse cortex between HPC and
ischemia predicted that cPKCβII, γ, and novel protein kinase
Cε (nPKCε)-interacting proteins as targets of the HPC-specific
miRNAs (90). Together, these studies support that HPC-induced
protection against ischemia involves regulation of cPKC proteins
and modulation of calcium signaling in mouse brain.
Anesthetic preconditioning
Several experimental studies show that inhalational anesthet-
ics serve as preconditioning agents that lead to neuroprotection
against stroke. Administration of isoflurane, halothane, sevoflu-
rane, desflurane, nitrous oxide, and other agents is protective in
the setting of stroke, and potential mechanisms of anesthetic pre-
conditioning include antagonism of AMPA and NMDA receptors
and reduced excitotoxicity, modulation of cerebral catecholamine
release, direct anti-oxidant effects of anesthesia, and reduction of
the cerebral metabolic rate (91). Recent studies to examine the
contribution of miRNAs to anesthetic preconditioning revealed
that isoflurane significantly increased expression of miR-203 in
rat B35 neuron-like cells, and there was a trend toward increased
miR-203 expression in rat cerebral cortex after isoflurane expo-
sure (92). Overexpression of miR-203 in B35 cells increased both
tolerance to ischemia and expression of Phospho-Akt, a protein
kinase that promotes cell survival. The effect of sevoflurane pre-
conditioning on rat brain miRNA expression following transient
cerebral ischemia revealed 3 upregulated and 9 downregulated
miRNAs (93). Among these, miR-15b expression was increased
after ischemia, while sevoflurane preconditioning downregulated
miR-15b expression and increased expression of Bcl-2, a target
of miR-15b. These studies suggest that sevoflurane may exert
anti-apoptotic effects by inhibiting miR-15b expression leading
to increased expression of Bcl-2.
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Toll-like receptor preconditioning
Preconditioning can be induced by activation of the Toll-like
receptors (94, 95). CpG oligodeoxynucleotide is a Toll-like recep-
tor 9 agonist that when administered 72 h prior to ischemia can
reduce injury in rodent and non-human primate models of exper-
imental stroke (96, 97). MiRNA expression studies in adult male
mice revealed that miRNAs are not regulated at 3, 24, or 72 h
after CpG preconditioning (98), suggesting that alterations in
miRNA expression in the brain are not necessary for the neuropro-
tection induced by systemic CpG preconditioning. Interestingly,
CpG-preconditioned mice had fewer total miRNAs regulated in
response to MCAO compared with saline-treated mice (57 vs. 73
miRNAs), suggesting that CpG preconditioning alters the miRNA
response to stroke (98). Subsequent analysis of the miRNAs dif-
ferentially expressed in CpG-preconditioned and saline-treated
mice at 24 h after stroke revealed that miRNA suppression corre-
lated with the upregulation of genes involved in neuroprotection,
suggesting that suppression of differential miRNAs in CpG pre-
conditioning may reprogram the genomic response to stroke to
favor a protective outcome.
Hibernation torpor
Torpor is a form of sleep that helps animals conserve valuable
resources in times of stress, such as in cold or very hot, dry weather.
Hibernation torpor (HT) is used to model endogenous mecha-
nisms of tolerance, as metabolic rates decrease in order to conserve
energy in both conditions. HT induces massive global SUMOyla-
tion in ground squirrels, and overexpression of Ubc9, SUMO-1, or
SUMO-2/3 is protective against ischemic injury in cortical neurons
subjected to OGD, and in mouse brain (99, 100). SUMO conjuga-
tion and global protein conjugation by ubiquitin-like modifiers
(ULMs) including NEDD8, ISG15, UFM1, and FUB1 signifi-
cantly increased in ground squirrel brain during HT. MiRNA
analysis of ground squirrel brain during HT revealed that the
miR-200 and miR-182 families were among the most consistently
depressed miRNAs relative to active animals (101). Inhibition of
these miRNA families in SHSY5Y cells resulted in increased global
protein conjugation and tolerance to OGD-induced cell death
(101). These studies link endogenous tolerance to brain ischemia
in hibernating animals to the regulation of a broad range of ULMs
via repression of miRNAs.
NEUROPROTECTION VIA MANIPULATION OF miRNAs AND/OR THEIR
TARGETS
The previous studies support that manipulation of specific
miRNAs or their targets altered by IPC or ischemia may be trans-
lated into viable neuroprotective strategies for stroke. Identified
targets thus far include epigenetic modifiers, heat shock pro-
teins, ubiquitin modifiers, DNA repair and cell cycle proteins,
autophagosome assembly proteins, and mediators of inflamma-
tory responses to injury in astrocytes.
miR-29
Previous studies showed that miR-29 is highly expressed in
adult rat brain, and is significantly downregulated by focal
ischemia (51). Bioinformatic analysis revealed DNA (cytosine-5)-
methyltransferase 3a (DNMT3a) as a target of miR-29c, suggest-
ing that increased DNMT3a expression in ischemic brain may
contribute to stroke injury (102). Indeed, treatment with premiR-
29c was protective against ischemia both in vitro (PC12 cells) and
in vivo, suggesting that strategies to replace miR-29c may decrease
cell death following ischemia. In addition, the miR-29c gene pro-
moter region contains binding sites for REST, and treatment of
PC12 cells with REST siRNA prevented ischemia-induced down-
regulation of miR-29c, which maintained repression of DNMT3a
resulting in significantly reduced ischemic cell death (102).
miR-132
Studies show that miR-132 is a neuron-specific miRNA that con-
tains a RE1 site within its promoter regions in mouse and is
a validated target of REST in mammalian cells (19). Transient
global ischemia markedly decreased miR-132 expression in rat
hippocampal CA1 cells at 24 and 48 h after ischemia, due to
ischemia-induced enrichment of REST at the miR-132 promoter
and repressed expression of miR-132 (103). REST-dependent
silencing was specific to miR-132, as REST did not alter expression
of miR-9 or miR-124a that also has RE1 sites in their promoter
regions. In addition, the repression of miR-132 was selectively
induced in vulnerable CA1 neurons, but not in CA3 neurons, sup-
porting that REST-dependent repression of miR-132 is critical
to ischemia-induced neuronal death (103). Depletion of REST
in vivo blocked ischemia-induced loss of miR-132 in hippocampal
neurons, while overexpression of miR-132 in vitro and in vivo
afforded robust protection against ischemia-induced neuronal
death. These studies support that REST-dependent repression of
miR-132 induces neuronal death in global ischemia.
miR-181b and miR-134
The expression of miR-181b and miR-134 is decreased by HPC
and ischemia in adult mouse cortex, but increased in tolerant
brain (90). Targets for miR-181b include heat shock protein A5
(HSPA5) and ubiquitin carboxyl-terminal hydrolase isozyme L1
(UCHL1), and expression of miR-181b in N2A cells repressed
HSPA5 and UCHL1 and protected cells against OGD-induced cell
death. Further, miR-181b antagomirs reduced caspase-3 cleavage
and neuronal cell loss in ischemic cortex and improved neuro-
logical deficits in mice after ischemia (104). A subsequent study
showed that downregulation of miR-134 in mouse N2A cells is
protective against OGD by upregulating heat shock protein A12B
(HSPA12B) (105). HSPA12B was validated as a target of miR-134,
and increased expression of HSPA12B correlated with attenua-
tion of neural cell damage in OGD-treated N2A cells, and reduced
infarct size and improved neurological outcomes in mice with
ischemic stroke (4).
miR-30a
Downregulation of miR-30a following ischemia in N2A cells and
in mouse brain correlated with an increased conversion ratio of
LC3 (microtubule-associated protein 1 light chain 3)-II/LC3-I and
increased expression of Beclin 1, which are required for formation
of the autophagosome (106).
miR-124
Ischemia leads to reduced expression of miR-124 in rat brain (107,
108) and downregulation of miR-124 in rats subjected to focal
ischemia correlated with increased expression of Ku70, a DNA
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repair protein. In vivo administration of a miR-124 antagomir
into rat brain increased expression of Ku70 mRNA and protein
in the ischemic region, resulting in reduced cell death and infarct
size, and improved neurological outcomes in rat (109).
miR-424
Expression of miR-424 is decreased in the plasma of patients
with acute ischemic stroke, and in mouse plasma and brain after
ischemia (110). Overexpression of miR-424 decreased infarct size
and brain edema due to MCAO when administered either pre-
or post-treatment. MiR-424 mimics reduced mRNA and protein
levels of cell division cycle 25 homolog A (CDC25A), cyclin D1,
and cell division protein kinase 6 (CDK6) in BV2 microglial cells,
all of which are upregulated in ischemic brain (110).
miR-103-1
Recent studies examined miR-103-1 as a treatment strategy
for stroke, based on its potential to regulate the expression of
the Na+/Ca2+ exchanger (NCX1), which mediates bidirectional
flux of calcium and sodium across the synaptic membrane and
increases ischemic damage in rat brain (111). NCX1 was validated
as a target of miR-103-1 in cortical neurons, and intracerebroven-
tricular infusion of anti-miR-103-1 not only prevented NCX1
reduction induced by stroke but also significantly reduced the
extent of brain ischemia when infused 24 h before stroke onset
(112).
Astrocyte miRNAs
Ischemic brain extract contains factors that elicit increased expres-
sion of stromal cell-derived factor-1 (SDF-1), a chemokine that
is induced by proinflammatory stimuli and that activates leuko-
cytes, in C6 cells and primary astrocytes (113). SDF-1 expression
increased in preconditioned astrocytes contributes to brain toler-
ance via the regulation of the miR-223/miR-27b pathways (113).
Neuroprotection by manipulation of miRNA-related pathways are
also found in astrocyte-rich miRNAs, including miR-181 and miR-
29 families, and miR-146a, and their validated targets, GRP78, and
Bcl-2 family members (114).
EFFECTS OF POST-STROKE NEUROPROTECTIVE THERAPIES ON miRNAs
Recent studies show that post-stroke therapies can effectively regu-
late the expression of miRNAs and their targets, and these miRNAs
may serve as direct targets for clinical intervention in stroke. For
example, post-stroke treatment of rats with valproic acid, a his-
tone deacetylase inhibitor and a mood stabilizer, upregulated the
expression of several miRNAs including miR-331 and miR-885-
3p, and improved neurological deficits and motor performance
following ischemia (115). In addition, studies show that using
Velcade (a proteasome inhibitor that may also suppress TLR sig-
naling) administered in combination with tissue plasminogen
activator (tPA) is neuroprotective against ischemia in aged rats
(116). The combination of Velcade plus tPA resulted in increased
levels of miR-l46a on cerebral endothelial cells, which express
TLRs, and outcomes were associated with reduced expression of
vascular interleukin-1 receptor-activated kinases 1 (116). Further,
it is well known that ischemic injury is more severe in older
animals as compared to younger animals, and this difference is
associated with reduced availability of insulin-like growth factor-1
(IGF-1) whose levels decrease with age. IGF-1 infusion follow-
ing stroke, which prevents estrogen neurotoxicity in middle-aged
female rats, altered the expression of two conserved IGF path-
way regulatory miRNAs, Let-7f, and miR-1. Adult female rats
treated with anti-miR-1 as late as 4 h after ischemia had signif-
icantly reduced cortical infarct volume, and anti-Let-7 robustly
reduced both cortical and striatal infarcts and preserved sensori-
motor function and inter-hemispheric neural integration (117).
However, anti-Let-7 was only effective in intact females and had
no effect on males or ovariectomized females, indicating that the
gonadal steroid environment critically modifies miRNA action
(117). Further studies examined the effect of post-stroke IGF-
1 treatment on miRNA expression in middle-aged female rats
(118). IGF-1 administered immediately after ischemia signifi-
cantly reduced infarct volume in 9- to 11-month female rats 24 h
after stroke. Post-stroke IGF-1 treatment significantly downregu-
lated 8 out of 168 disease-related miRNAs in tissue isolated 4 h
after ischemia. KEGG pathway analysis predicted that targets of
these miRNAs include proteins involved in PI3K–Akt signaling,
cell adhesion/ECM receptor pathways, and T-and B-cell signal-
ing. Further, Phospho-Akt was reduced by 4 h after ischemia, but
was elevated by IGF-1 treatment at 24 h after ischemia. IGF-1 also
induced Akt activation, an effect that was preceded by a reduction
of BBB permeability and global suppression of cytokines at 4 h
post-stroke (118).
CONCLUSION
The goal of this review was to present the current state of knowl-
edge regarding ncRNAs and their role(s) in stroke and neuropro-
tection. However, of these three relatively new families of ncRNAs,
miRNAs are the most well studied to date. Yet the lncRNAs and
piRNAs are certain to contribute to the setting of ischemia and
neuroprotection, and there are several important future lines of
investigation for all ncRNA studies. The foregoing studies high-
light the difficulty of analyzing miRNA expression data, due to
the diversity of ischemia and neuroprotection models, the time
points examined, and the fact that since miRNAs can act in con-
cert to exert effects on target mRNAs, focus on a single miRNA
is unlikely to realistically capture endogenous responses. Thus,
the first such studies must focus on ways to meaningfully trans-
late the outcome of multiple expression profiling studies from
diverse labs in order to identify global signaling pathways or tar-
gets that have been underappreciated to date. To address this
issue, Xiao and colleagues sought to model complex interactions
in order to identify synergistic effects within miRNA responses
to brain ischemia (119). miRNA array expression data submit-
ted to the Gene Expression Omnibus database from multiple
studies in different labs were examined to identify mouse brain
miRNAs differentially expressed between ischemia and control.
Common predicted targets of the miRNAs were then used as a
candidate subset to identify functional modules. An miRNA func-
tional synergistic network, constructed by assembling all miRNA
synergistic pairs, revealed 51 differentially expressed miRNAs
identified between ischemia and control (32 upregulated and 19
downregulated). Among them, 24 miRNAs commonly regulat-
ing at least one target gene were used to construct a network.
Subsequent analyses revealed 16 miRNAs forming 20 miRNA
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interaction pairs that participated in inflammatory responses,
suggesting these 16 miRNAs as underlying targets for preven-
tion and/or treatment of stroke (119). These analyses highlight
that the power of global miRNA and ncRNA studies lies in their
potential to identify proteins or pathways involved in responses
to ischemia. The second such studies must address the need to
identify the effects of ncRNAs acting in concert to regulate cel-
lular phenotypes or responses to stress. To date, each family of
ncRNA has largely been examined individually, due to techni-
cal barriers to combinatorial analysis of all ncRNAs. RNAseq
studies can be used to identify all RNA species in a given sam-
ple set, but even this method is limited in the ability to analyze
distinct sizes of RNA species. Thus, lncRNAs (>200 nt) are not
yet typically sequenced together with small ncRNAs such as the
miRNAs and piRNAs (~20–36 nt). A third line of exciting stud-
ies will come from the not-so-recent finding that extracellular
RNAs exist in biofluids, mostly contained within EVs such as
microvesicles, and can serve as biomarkers of neurological disor-
ders (120). EVs and their molecular components are increasingly
shown to be effectors of cell–cell communication in the brain
and their uptake can alter the phenotype of a recipient cell (32).
Thus, future lines of investigation should include examining the
consequences of disrupted blood flow and metabolism, such as
during a stroke, on communication mediated by EVs. Further,
given that EVs mediate communication between distinct cell types
in the brain, future therapeutic strategies for the treatment or
prevention of stroke and other brain disorders might include
focused delivery of molecular or pharmaceutical agents by EVs,
potentially using vesicles isolated from ones own biofluids. The
importance and excitement of such studies is highlighted by the
recent formation of the Extracellular RNA Communication pro-
gram (http://commonfund.nih.gov/Exrna/index) supported by
the National Institutes of Health Common Fund that aims to dis-
cover fundamental biological principles about the mechanisms
of exRNA generation, secretion, and transport; to identify and
develop a catalog of exRNA in normal human body fluids; and
to investigate the potential for using exRNAs as therapeutic mol-
ecules or biomarkers of disease. Thus, there are many new and
exciting future opportunities for research and development in
the field of ncRNAs, and in particular for their role in, contri-
bution to, and regulation of the treatment of human diseases,
including stroke.
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